This is a very significant point for Neuren. CNS is known as the graveyard of drug development. So many drugs have failed that many Pharma companies disbanded their CNS teams to stop wasting money on repeated failures.
This isn't because CNS isn't a big market (Alzheimers, stroke, TBI are all as big as you could get market wise), its because its been so hard to prove any benefits that outweigh side-effects.
The fact that Neuren may have one of the first approved neurodevelopment drugs that _also_ has potential for wider application in a CNS market with few successful drugs makes Neuren just that much more valuable.
Its easy to see why Jon struggles to contain his excitement about NNZ-2591. The facts above make Neuren's potential 'aspirin for the brain' inestimably more valuable.
NEU Price at posting:
$7.07 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)